PATIENT ID AGE/ SEX RURAL/URBAN CLNCAL TUMOR STAGE EXON CODON NUMBER NUCLEOTIDE NUMBER MUTATION BASE CHANGE AMINO ACID CHANGE EFFECT 8T 47/ F R GRADE II 5 142 13105 426InsA CCT>CCAT NS (Pro>Pro) FS 5 172 13195 516InsC GTT>GTCT NS (Val>Val) FS 5 179 13214 535InsG CAT>GCAT NS (His>Ala) FS 12L 52/M R GRADE III 5 170 13189 510InsT ACG>ACTG NS (Thr>Thr) (at CpG) FS 5 173 13197 518delT GTG>G_G NS (Val>Gly) FS 6 216&217 13775  649InsT _GTG>TGTG NS (Val>Cys) FS 16L 62/M U   GRADE III 5 142 13105 426InsA CCT>CCAT NS (Pro>Pro) FS 5 144 13110 431A>T CAG>CTG Gln>Leu MS 5 179 13215 536InsG CAT>CGAT NS (His>Arg) FS 5 180 13217 538InsA GAG>AGAG NS (Glu>Arg) FS 23L 57/M R GRADE III 5 142 13105 426InsA CCT>CCAT NS (Pro>Pro) FS 5 157 13150 471C>A GTC>GTA  (Val>Val) Silent 5 173 13196 517InsC GTG>CGTG NS (Val>Arg) FS 24L 54/M R GRADE III 5 169 13185 506T>G ATG>AGG Met>Arg MS 5 170 13189 510InsT ACG>ACTG NS Thr>Thr FS

Table 3: Clinico-epidemiological details and nature of TP53 mutation spectrum in sporadic gastric adenocarcinoma patients from Kashmir valley.